Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV-VPAC1 Cu-64
- Development stage
- Preclinical
- Lead developer
- NuView Life Sciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
NV-VPAC1 Cu-64 is a radiopharmaceutical diagnostic agent developed by NuView Life Sciences. It consists of a small molecule peptide analog that specifically targets the vasoactive intestinal peptide receptor type 1 (VPAC1), a G protein-coupled receptor (GPCR) that is significantly overexpressed on the surface of various malignant cells, including those in prostate, breast, bladder, and brain cancers. By chelating the positron-emitting radioisotope Copper-64 (Cu-64), the molecule acts as a radiotracer for Positron Emission Tomography (PET) imaging. This allows for the high-specificity identification and localization of primary and metastatic tumors. The platform is part of a theranostic approach, where Cu-64 is used for imaging and Cu-67 is used for targeted radiotherapy.
- Other names
- NV-VPAC1 (Cu-64 PET imaging)Cu-64-NV-VPAC1Cu64-NV-VPAC1Cu 64-NV-VPAC1
02
Targets
VIPR1 (Vasoactive intestinal peptide receptor 1)
Beyond the preview
Go deeper on NV-VPAC1 Cu-64.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV-VPAC1 Cu-64.